Skip to main content

Table 2 Clinical characteristics of the 52 enrolled patients

From: Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy

Variable All patients (n = 52) NAC (n = 20) Non-NAC (n = 32) P
Age (years)     0.350
 < 65 35 (67.3) 15 (75.0) 20 (62.5)  
 65 17 (22.7) 5 (25.0) 12 (37.5)  
Gender     0.508
 Male 29 (55.8) 10 (50.0) 19 (59.4)  
 Female 23 (44.2) 10 (50.0) 13 (40.6)  
Body mass index (kg/m2) 22.5 ± 3.5 22.8 ± 3.3 22.4 ± 3.6 0.542
Preoperative CEA level (ng/ml)     0.744
 < 5 17 (32.7) 6 (30.0) 11 (34.4)  
 ≥ 5 35 (67.3) 14 (70.0) 21 (65.6)  
Comorbidity 14 (26.9) 4 (20.0) 10 (31.3) 0.374
Tumour location     0.636
 Colon 42 (80.8) 15 (75.0) 27 (84.4)  
 Rectum 10 (19.2) 5 (25.0) 5 (15.6)  
Histology     0.289
 Adenocarcinoma 29 (55.8) 13 (65.0) 16 (50.0)  
 Mucinous/signet-ring 23 (44.2) 7 (35.0) 16 (50.0)  
T stage     0.287
 T3 6 (11.5) 4 (20.0) 2 (6.3)  
 T4 46 (88.5) 16 (80.0) 30 (93.7)  
N stage     0.506
 N0 8 (15.4) 3 (15.0) 5 (15.6)  
 N1 16 (30.8) 8 (40.0) 8 (25.0)  
 N2 28 (53.8) 9 (45.0) 19 (59.4)  
PCI score     0.031
 < 12 32 (61.5) 16 (80.0) 16 (50.0)  
 ≥ 12 20 (38.5) 4 (20.0) 16 (50.0)  
PCI score 11.9 ± 5.6 9.8 ± 4.7 13.7 ± 6.4 0.006
Liver metastases 9 (17.3) 4 (20.0) 5 (15.6) 0.977
Ascites 22 (42.3) 8 (40.0) 14 (43.8) 0.790
HIPEC regimen     0.930
 Lobaplatin+oxaliplatin+raltitrexed 23 (44.2) 9 (45.0) 14 (43.8)  
 Oxaliplatin+faltitrexed 29 (55.8) 11 (55.0) 18 (56.2)  
CC score     0.018
 0–1 31 (59.6) 16 (80.0) 15 (46.9)  
 2–3 21 (40.4) 4 (20.0) 17 (53.1)  
Adjuvant chemotherapy     0.738
 Yes 44 (84.6) 16 (80.0) 28 (87.5)  
 No 8 (15.4) 4 (20.0) 4 (12.5)  
  1. PCI peritoneal carcinomatosis index, CC cytoreduction score